Monte Rosa Therapeutics (GLUE) Cash from Financing Activities (2020 - 2026)

Monte Rosa Therapeutics' Cash from Financing Activities history runs 7 years deep, the most recent figure standing at $328.3 million for Q1 2026.

• On a quarterly basis, Cash from Financing Activities rose 2345150.0% year-over-year to $328.3 million in Q1 2026; TTM through Mar 2026 was $358.7 million, a 263.54% increase from a year earlier, with the FY2025 full-year figure at $30.4 million, down 69.31% from the prior year.
• Cash from Financing Activities advanced to $328.3 million in Q1 2026 per GLUE's latest filing, from $29.6 million in the prior quarter.
• Across five years, Cash from Financing Activities topped out at $328.3 million in Q1 2026 and bottomed at -$217000.0 in Q3 2022.
• The 5-year median for Cash from Financing Activities is $365000.0 (2025), against an average of $29.7 million.
• Across the five-year window, Cash from Financing Activities slumped 100.74% in 2022 and soared 2345150.0% in 2026, its largest moves.
• Year by year, Cash from Financing Activities stood at $20.4 million in 2022, then rose by 23.19% to $25.2 million in 2023, then slumped by 97.58% to $608000.0 in 2024, then surged by 4772.37% to $29.6 million in 2025, then jumped by 1008.34% to $328.3 million in 2026.
• Per Business Quant, the three latest GLUE Cash from Financing Activities figures stand at $328.3 million (Q1 2026), $29.6 million (Q4 2025), and $348000.0 (Q3 2025).